Topica Pharmaceuticals

Topica Pharmaceuticals is a clinical research stage company focused on developing luliconazole for the treatment of onychomycosis, a common nail fungal infection affecting over 35 million Americans. Luliconazole has shown potent anti-fungal properties and a favorable safety profile, with the ability to penetrate the nail plate effectively. The company completed a Phase 1/2a clinical trial in 2011, demonstrating the swift nail plate penetration and patient tolerance of a 10 percent luliconazole solution. With its last $31.52M Venture Round investment in June 2013, Topica Pharmaceuticals is now dedicated to conducting dose-finding and efficacy studies, aiming to introduce luliconazole as the first highly effective and safe topical therapy for onychomycosis. The company operates in the Biotechnology, Medical Devices, and Pharmaceutical industries and was founded in 2004.